{"id":970619,"date":"2026-06-04T08:41:10","date_gmt":"2026-06-04T12:41:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/"},"modified":"2026-06-04T08:41:10","modified_gmt":"2026-06-04T12:41:10","slug":"teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/","title":{"rendered":"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <em>AHZANTIVE<sup>\u00ae<\/sup>\u00a0(aflibercept)\u00a0is\u00a0an EMA-approved\u00a0biosimilar to Eylea<sup>\u00ae<\/sup> (aflibercept)\u00a0with\u00a0demonstrated\u00a0similarity in efficacy,\u00a0safety\u00a0and immunogenicity to the reference product\u00a0<\/em>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <em>The launch\u00a0expands\u00a0Teva\u2019s biosimilars portfolio\u00a0and presence in ophthalmology,\u00a0in line with\u00a0the\u00a0Company\u2019s Pivot\u00a0to Growth strategy\u00a0\u00a0<\/em>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <em>Teva\u00a0continues to broaden availability of\u00a0biosimilars\u00a0in Europe\u00a0reinforcing\u00a0the\u00a0Company\u2019s commitment to improving patient access to biologic medicines<\/em><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">TEL\u00a0AVIV,\u00a0Israel, June  04, 2026  (GLOBE NEWSWIRE) &#8212; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)\u00a0today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea<sup>\u00ae<\/sup>, in\u00a0Europe\u00a0further strengthening the\u00a0Company\u2019s growing biosimilars portfolio and expanding its presence in ophthalmology.\u00a0The launch reflects Teva\u2019s strategy to build a leading\u00a0biosimilars\u00a0business in areas of significant patient need and to broaden access to biologic medicines\u00a0through strong partnerships, broad commercial capabilities,\u00a0and reliable supply.\u00a0\u00a0<\/p>\n<p align=\"justify\">The\u00a0launch of AHZANTIVE pre-filled syringes\u00a0began\u00a0in May 2026 across several European markets, including France, Germany, Spain,\u00a0and\u00a0The Netherlands.\u00a0\u00a0The launch supports broader availability of biosimilar treatment options for patients living with serious retinal diseases and provides healthcare professionals with\u00a0additional\u00a0high-quality therapeutic choices.\u00a0Teva\u00a0expects to\u00a0launch in\u00a0additional\u00a0markets later this year.\u00a0The launch follows Teva\u2019s semi-exclusive commercialization agreement with Klinge Biopharma GmbH and\u00a0Formycon\u00a0AG in major parts of Europe and Israel.\u00a0\u00a0<\/p>\n<p align=\"justify\">AHZANTIVE is a biosimilar to Eylea<sup>\u00ae<\/sup> (aflibercept), with comparable efficacy,\u00a0safety\u00a0and immunogenicity to the reference product. It\u00a0received\u00a0European Commission\u00a0approval\u00a0in 2025\u00a0for\u00a0the treatment\u00a0of\u00a0Neovascular\u00a0Age-Related (&#8216;wet&#8217;) Macular Degeneration (nAMD) and other serious retinal diseases such as Diabetic Macular Edema (DME), visual impairment due to Myopic Choroidal\u00a0Neovascularisation\u00a0(CNV) and Macular Edema following Retinal Vein Occlusion (RVO).\u00a0These chronic, vision-threatening conditions can create a significant burden for patients,\u00a0caregivers\u00a0and healthcare systems.\u00a0<\/p>\n<p align=\"justify\">\u201cBiosimilars play\u00a0a\u00a0critical role in sustainable healthcare systems,\u201d said Yolanda Tibbe, Global Head of Biosimilars at Teva. \u201cWith this launch, we are expanding our biosimilars portfolio with an important treatment option for people living with serious conditions that can threaten sight.\u201d\u00a0<\/p>\n<p align=\"justify\">Teva has one of\u00a0the\u00a0world\u2019s largest\u00a0portfolios of\u00a0biosimilars globally, with\u00a011\u00a0biosimilars\u00a0in market\u00a0and\u00a013 products\u00a0in pipeline across key therapeutic areas including oncology, immunology,\u00a0ophthalmology\u00a0and respiratory care.\u00a0The\u00a0Company\u00a0continues to expand its biosimilar footprint through strategic partnerships, commercial\u00a0excellence\u00a0and long-term commitment to improving\u00a0patient\u00a0access to biologic medicines.\u00a0\u00a0<\/p>\n<p align=\"justify\">Learn more about Teva\u2019s global biosimilars portfolio and commercialization capabilities at\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jvNTm4OmJFgpdRG45je-i1nnb4x_XvZsWTkzsqe4Rd8N73K2l-sQWTO9UqKVSXqmpR3PrijMHgVHNtIF2yHw0cLsFJ61KTFf3Q5lqRWQ22edml7Dnf0vsaiKBSc95d10m0FVv-jiYG8E7n3PXBPZgTj0vW0amk0JRzGrTFyvKGv-8l1WYvpQJcH-WheaqLBhiBE-wlliRpADp444yamIPWBONnB0TWLTeq4alCiwC4zzMCFHmS6rCJZ9YwUL8xmbmUoKp2Oe1KHd2ZQhW9mUzdueRk03Nct67Cumr6oppgE=\" rel=\"nofollow\" target=\"_blank\">www.tevabiosimilars.com<\/a>.\u00a0<\/p>\n<p>\n        <strong>About\u00a0AHZANTIVE\u00a0<\/strong>\n      <\/p>\n<p>AHZANTIVE\u00a0is a medicine used to treat adults with:\u00a0<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Neovascular\u00a0(&#8216;wet&#8217;)\u00a0age-related macular degeneration (AMD),\u00a0in which abnormal blood vessel growth beneath the macula\u00a0(central part of the retina)\u00a0leads to fluid\u00a0and blood\u00a0leakage, swelling and progressive central vision\u00a0loss;\u00a0<\/li>\n<li style=\"margin-bottom:8pt\">impaired vision due to macular oedema (swelling)\u00a0secondary\u00a0to\u00a0retinal\u00a0vein\u00a0occlusion\u00a0(RVO), including\u00a0central\u00a0(CRVO)\u00a0and\u00a0branch\u00a0forms\u00a0(BRVO);\u00a0<\/li>\n<li style=\"margin-bottom:8pt\">impaired vision due to\u00a0diabetic\u00a0macular oedema\u00a0(DME);\u00a0<\/li>\n<li style=\"margin-bottom:8pt\">impaired vision due to myopic choroidal neovascularization (mCNV), a serious complication of pathological myopia (severe short-sightedness) in which abnormal blood vessels develop beneath the retina, leading to progressive vision loss.\n<\/li>\n<\/ul>\n<p align=\"justify\">AHZANTIVE\u00a0contains\u00a0the active substance aflibercept and is a \u2018biosimilar medicine\u2019;\u00a0this means that\u00a0AHZANTIVE\u00a0is highly similar to another biological\u00a0medicine\u00a0(the \u2018reference medicine\u2019) that is already\u00a0authorized\u00a0in the EU. The reference medicine for\u00a0AHZANTIVE\u00a0is Eylea<sup>\u00ae<\/sup>.\u00a0\u00a0<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4nmDnMqmwVxXMZ_v9chCdI1Uq58jteFlaeOz3UFkAEKrvXdN0TDLRvlw5sCA9Q2FVlgTLRXDcHlXlwrN2PNtbAZtelyRKPmdYYgzg5GQhAY_jiNSXitnL1LZ7JDmbWHlIfuZL168bSGAjwk2YQnz_kJXp2A7blPObXbHnZYNxoVGfF4k8XjMV2VqicNMyaPex9vQWETPNs6wb3fVYCTvew==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ahzantive<\/a>\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About Teva\u00a0<\/strong>\n      <\/p>\n<p align=\"justify\">Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class\u00a0generics\u00a0business. For over 120 years, Teva\u2019s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines,\u00a0biosimilars\u00a0and pharmacy brands worldwide, Teva is dedicated to addressing patients\u2019 needs, now and in the future. At Teva, We Are All\u00a0In\u00a0For\u00a0Better Health. To learn more about how, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jvNTm4OmJFgpdRG45je-ixuyyAERFHFsbUHjYZKE7e7bQ-Y-sTxc3zzAzsnS2UHL3nbXtV9jgYYP6Q8VtgT4j6IFi3dCo1q9Vr5SkiCGEJo=\" rel=\"nofollow\" target=\"_blank\">www.tevapharm.com<\/a>.\u00a0<\/p>\n<p>*Eylea<sup>\u00ae<\/sup>\u00a0is\u00a0a\u00a0registered\u00a0trademark\u00a0of\u00a0Regeneron\u00a0Pharmaceuticals Inc.\u00a0\u00a0<\/p>\n<p>**AHZANTIVE<sup>\u00ae<\/sup>\u00a0is\u00a0a\u00a0registered\u00a0trademark\u00a0of\u00a0Klinge\u00a0Biopharma\u00a0GmbH\u00a0<\/p>\n<p>\n        <strong>Teva Cautionary Note Regarding Forward Looking Statements<\/strong>\u00a0\u00a0<\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management\u2019s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as \u201cshould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201ctarget,\u201d \u201cmay,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve\u201d and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial\u00a0performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully commercialize\u00a0AHZANTIVE (aflibercept), a biosimilar to Eylea<sup>\u00ae<\/sup>, in Europe; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in this press release, in\u00a0our Quarterly Report on Form 10-Q for the first quarter of 2026, and in\u00a0our\u00a0Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned \u201cRisk Factors\u201d and \u201cForward-Looking Statements.\u201d Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information\u00a0contained\u00a0herein, whether\u00a0as a result of\u00a0new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.\u00a0<\/p>\n<p>\n        <strong>Teva Media Inquiries<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RPtDzosXt-7tHAqlr3AnvGfZJHaRl71dUjOq6A3Zcmfisr2_nZrE_bI9yKRMN_8iBH5eT1fnY2MKDXqVZ39ni9Mbl7FSkiFCVZTNGCuCP4xkq19c09s5ooMSaoGhSbEWIqa3mWh3ghGnE7dw_mOBSfec0Eh7nBUXildt9SEVpeo=\" rel=\"nofollow\" target=\"_blank\">TevaCommunicationsNorthAmerica@tevapharm.com<\/a><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Teva Investor Relations Inquires<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RPtDzosXt-7tHAqlr3AnvM3klpkDvMoLM7qxx1-_6tZVukuAi30pC2iujnNwxObX8FMAbpkCs_GwuA4HFDqugDGI5LG6BieUWmZ_etaXg_c=\" rel=\"nofollow\" target=\"_blank\">TevaIR@Tevapharm.com<\/a><br \/>\n        <\/strong>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/OGM0NWI0ZGQtOWNkYy00MjNmLWFlYTQtMWI2NjBlNGU2NDY2LTEwMTQ2NTAtMjAyNi0wNi0wNC1lbg==\/tiny\/Teva-Pharmaceutical-Industries.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AHZANTIVE\u00ae\u00a0(aflibercept)\u00a0is\u00a0an EMA-approved\u00a0biosimilar to Eylea\u00ae (aflibercept)\u00a0with\u00a0demonstrated\u00a0similarity in efficacy,\u00a0safety\u00a0and immunogenicity to the reference product\u00a0 The launch\u00a0expands\u00a0Teva\u2019s biosimilars portfolio\u00a0and presence in ophthalmology,\u00a0in line with\u00a0the\u00a0Company\u2019s Pivot\u00a0to Growth strategy\u00a0\u00a0 Teva\u00a0continues to broaden availability of\u00a0biosimilars\u00a0in Europe\u00a0reinforcing\u00a0the\u00a0Company\u2019s commitment to improving patient access to biologic medicines TEL\u00a0AVIV,\u00a0Israel, June 04, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)\u00a0today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea\u00ae, in\u00a0Europe\u00a0further strengthening the\u00a0Company\u2019s growing biosimilars portfolio and expanding its presence in ophthalmology.\u00a0The launch reflects Teva\u2019s strategy to build a leading\u00a0biosimilars\u00a0business in areas of significant patient need and to broaden access to biologic medicines\u00a0through strong partnerships, broad commercial capabilities,\u00a0and reliable supply.\u00a0\u00a0 The\u00a0launch of AHZANTIVE pre-filled syringes\u00a0began\u00a0in May 2026 across several European markets, including France, Germany, Spain,\u00a0and\u00a0The Netherlands.\u00a0\u00a0The launch &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-970619","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AHZANTIVE\u00ae\u00a0(aflibercept)\u00a0is\u00a0an EMA-approved\u00a0biosimilar to Eylea\u00ae (aflibercept)\u00a0with\u00a0demonstrated\u00a0similarity in efficacy,\u00a0safety\u00a0and immunogenicity to the reference product\u00a0 The launch\u00a0expands\u00a0Teva\u2019s biosimilars portfolio\u00a0and presence in ophthalmology,\u00a0in line with\u00a0the\u00a0Company\u2019s Pivot\u00a0to Growth strategy\u00a0\u00a0 Teva\u00a0continues to broaden availability of\u00a0biosimilars\u00a0in Europe\u00a0reinforcing\u00a0the\u00a0Company\u2019s commitment to improving patient access to biologic medicines TEL\u00a0AVIV,\u00a0Israel, June 04, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)\u00a0today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea\u00ae, in\u00a0Europe\u00a0further strengthening the\u00a0Company\u2019s growing biosimilars portfolio and expanding its presence in ophthalmology.\u00a0The launch reflects Teva\u2019s strategy to build a leading\u00a0biosimilars\u00a0business in areas of significant patient need and to broaden access to biologic medicines\u00a0through strong partnerships, broad commercial capabilities,\u00a0and reliable supply.\u00a0\u00a0 The\u00a0launch of AHZANTIVE pre-filled syringes\u00a0began\u00a0in May 2026 across several European markets, including France, Germany, Spain,\u00a0and\u00a0The Netherlands.\u00a0\u00a0The launch &hellip; Continue reading &quot;Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T12:41:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae\",\"datePublished\":\"2026-06-04T12:41:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/\"},\"wordCount\":980,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/\",\"name\":\"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw==\",\"datePublished\":\"2026-06-04T12:41:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/","og_locale":"en_US","og_type":"article","og_title":"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae - Market Newsdesk","og_description":"AHZANTIVE\u00ae\u00a0(aflibercept)\u00a0is\u00a0an EMA-approved\u00a0biosimilar to Eylea\u00ae (aflibercept)\u00a0with\u00a0demonstrated\u00a0similarity in efficacy,\u00a0safety\u00a0and immunogenicity to the reference product\u00a0 The launch\u00a0expands\u00a0Teva\u2019s biosimilars portfolio\u00a0and presence in ophthalmology,\u00a0in line with\u00a0the\u00a0Company\u2019s Pivot\u00a0to Growth strategy\u00a0\u00a0 Teva\u00a0continues to broaden availability of\u00a0biosimilars\u00a0in Europe\u00a0reinforcing\u00a0the\u00a0Company\u2019s commitment to improving patient access to biologic medicines TEL\u00a0AVIV,\u00a0Israel, June 04, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)\u00a0today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea\u00ae, in\u00a0Europe\u00a0further strengthening the\u00a0Company\u2019s growing biosimilars portfolio and expanding its presence in ophthalmology.\u00a0The launch reflects Teva\u2019s strategy to build a leading\u00a0biosimilars\u00a0business in areas of significant patient need and to broaden access to biologic medicines\u00a0through strong partnerships, broad commercial capabilities,\u00a0and reliable supply.\u00a0\u00a0 The\u00a0launch of AHZANTIVE pre-filled syringes\u00a0began\u00a0in May 2026 across several European markets, including France, Germany, Spain,\u00a0and\u00a0The Netherlands.\u00a0\u00a0The launch &hellip; Continue reading \"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-04T12:41:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae","datePublished":"2026-06-04T12:41:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/"},"wordCount":980,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/","name":"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw==","datePublished":"2026-06-04T12:41:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NTc0MyM0MDI0MDMyNjMjMjAwMzA3Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Teva Expands European biosimilars portfolio with launch of\u00a0AHZANTIVE\u00ae\u00a0(aflibercept) biosimilar to Eylea\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=970619"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=970619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=970619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=970619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}